Fluoxetine

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H302：Gesundheitsschädlich bei Verschlucken.

  H315：Verursacht Hautreizungen.

  H319：Verursacht schwere Augenreizung.

  H335：Kann die Atemwege reizen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P264：Nach Gebrauch gründlich waschen.

  P264：Nach Gebrauch gründlich waschen.

  P270：Bei Gebrauch nicht essen, trinken oder rauchen.

  P271：Nur im Freien oder in gut belüfteten Räumen verwenden.

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P301+P312：BEI VERSCHLUCKEN: Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

  P302+P352：BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.

  P304+P340：BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen.

  P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

  P330：Mund ausspülen.

  P332+P313：Bei Hautreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

  P337+P313：Bei anhaltender Augenreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

  P362：Kontaminierte Kleidung ausziehen und vor erneutem Tragen waschen.

  P403+P233：An einem gut belüfteten Ort aufbewahren. Behälter dicht verschlossen halten.

  P405：Unter Verschluss aufbewahren.

  P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Fluoxetine Chemische Eigenschaften,Einsatz,Produktion Methoden

• Originator

  Actan ,Eurolab

• History

  Prozac was discovered by a team of chemists at the pharmaceutical company Eli Lilly. Key researchers involved in the work were Bryan B. Molloy (1939–2004), Klaus K. Schmiegel (1939–), Ray W. Fuller (1935–1996), and David T. Wong (1935–). In the middle of the 20th century, the main group of drugs for treating depression was tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). TCAs are named because of their three-ring chemical structure. Lilly researchers were working with TCAs in the1950s and 1960s. Prozac was developed by Eli Lilly scientists who based their work on the antihistamine diphenylhydramine; diphenylhydramine hydrochloride is marketed under the trade name Benadryl.the Lilly scientists examined diphenylhydramine because research had demonstrated that some antihistamines, including diphenylhydramine, had the ability to inhibit serotonin and serve as antidepressants.Molloy started examining diphenylhydramine-type compounds for their antidepressant properties in 1970. Molloy and his colleagues discovered fluoxetine hydrochloride had potential as an antidepressant in 1972 and it was referred to as Lilly 110140 in thefirst published articles on the compound, which appeared in 1974. Fluoxetine hydrochloride was no more effective than other antidepressant drugs of the time, but it produced much fewer negative side effects because it interacted specifically with the neurotransmitter serotonin but did not interfere with other neurotransmitters. TCAs inhibited the reuptake of other neurotransmitters along with serotonin. Molloy and Schmiegel applied for a patent in 1974 for the synthesis of arloxyphenylpropylamines (U.S. Patent Number 4314081).the patent named a number of compounds in this class of chemicals that could be used as antidepressants. In 1983, Eli Lilly applied to the Food and Drug Administration (FDA) for approval of fluoxetine hydrochloride as a drug used to treat depression. Prozac was first offered to the public in Belgium in 1986 and in the United States in 1988. Eli Lilly initially had a monopoly on fluoxetine hydrochloride as an antidepressant with its Prozac brand. In the mid-1990s, a lawsuit filed against Eli Lilly led to the loss of their exclusive patent rights, allowing generic fluoxetine hydrochloride antidepressants to be marketed starting in 2001.

• Verwenden

  Fluoxetine in its hydrochloride salt form is marketed as numerous drugs, the most popular ofwhich is Prozac. Prozac is prescribed for depression, obsessive-compulsive disorder, bulimia,agoraphobia, and premenstrual dysphoric disorder (premenstrual syndrome). Prozac andother fluoxetine medications belong to a class of drugs called selective serotonin reuptakeinhibitors (SSRIs). When a nerve signal is sent, a neurotransmitter, such as serotonin, travelsfrom a presynaptic neuron across the synaptic gap to a postsynaptic neuron. Receptors on thepostsynaptic neuron capture the neurotransmitter, resulting in the transmission of the signal.After performing its function, the neurotransmitter is released back to the presynaptic cellin a process called reuptake. SSRIs slow down the return of serotonin to presynaptic neurons,allowing for a higher serotonin concentration on postsynaptic neurons. Because depressionand other psychological disorders are associated with low serotonin levels, Prozac and otherSSRIs help maintain serotonin levels.
  Prozac was thefirst SSRI antidepressant to be marketed. Because Prozac produced lesssevere side effects than other antidepressants, it became the drug of choice for treating depressionand was made available to a wider public. Its use exploded in the 1990s, with sales peakingin 2000 when revenues from Prozac reached $2.5 billion. Eli Lilly’s patent on fluoxetinehydrochloride expired in August 2001; its use continued into the 21st century but on a muchsmaller scale as generic fluoxetine hydrochloride products came on the market. Since its introductionin 1986, Prozac was the most prescribed drug for antidepressant until recent yearswhen it was replaced by Zoloft, Paxil, and Lexapro as the top three antidepressants prescribedin the United States, respectively.
  Fluoxetine hydrochloride is most recognized as an antidepressant, but it is also used torelieve symptoms of premenstrual dysphoric disorder (PMDD) (premenstrual syndrome).Th ese symptoms include mood swings, tension, bloating, irritability, and breast tenderness. EliLilly began marketing fl uoxetine hydrochloride as Sarafem in 2000 for treating PMDD.

• Verwenden

  Rivastigmine Metabolite

• Verwenden

  antibacterial

• Definition

  ChEBI: N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine is an aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group. It is a member of (trifluoromethyl)benzenes, an aromatic ether and a secondary amino compound.

• Manufacturing Process

  About 600 g of β-dimethylaminopropiophenone hydrochloride were converted to the corresponding free base by the action of 1.5 N aqueous sodium hydroxide. The liberated free base was taken up in ether, the ether layer separated and dried, and the ether removed therefrom in vacuo. The residual oil comprising β-dimethylaminopropiophenone was dissolved in 2 L of tetrahydrofuran, and the resulting solution added in dropwise fashion with stirring to a solution of four moles of diborane in 4 L of tetrahydrofuran. The reaction mixture was stirred overnight at room temperature. An additional mole of diborane in 1 L of tetrahydrofuran was added, and the reaction mixture stirred again overnight at room temperature. Next, 2 L of aqueous hydrochloric acid were added to decompose any excess diborane present. The tetrahydrofuran was removed by evaporation. The acidic solution was extracted twice with 1 L portions of benzene, and the benzene extracts were discarded. The acidic solution was then made basic with an excess of 5 N aqueous sodium hydroxide. The basic solution was extracted three times with 2 L portions of benzene. The benzene extracts were separated and combined, and the combined extracts washed with a saturated aqueous sodium chloride and then dried. Evaporation of the solvent in vacuo yields 442 g of N,Ndimethyl-3-phenyl-3-hydroxypropylamine.
  A solution containing 442 g of N,N-dimethyl-3-phenyl-3-hydroxypropylamine in 5 L of chloroform was saturated with dry gaseous hydrogen chloride. 400 ml of thionyl chloride were then added to the chloroform solution at a rate sufficient to maintain reflux. The solution was refluxed an additional 5 h. Evaporation of the chloroform and other volatile constituents in vacuo yielded N,N-dimethyl-3-phenyl-3-chloropropylamine hydrochloride which was collected by filtration, and the filter cake washed twice with 1500 ml portions of acetone. The washed crystals weighed about 500 g and melted at 181°-183°C with decomposition. An additional 30 g of compound were obtained from the acetone wash by standard crystallization procedures. The structure of the above compound was verified by NMR and titration.
  A solution of 50 g p-trifluoromethylphenol, 12 g of solid sodium hydroxide and 400 ml of methanol was placed in a 1 L round-bottom flask equipped with magnetic stirrer, condenser and drying tube. The reaction mixture was stirred until the sodium hydroxide had dissolved. Next, 29.8 g of N,N-dimethyl-3phenyl-3-chloropropylamine hydrochloride were added. The resulting reaction mixture was refluxed for about 5 days and then cooled. The methanol was then removed by evaporation, and the resulting residue taken up in a mixture of ether and 5 N aqueous sodium hydroxide. The ether layer was separated and washed twice with 5 N aqueous sodium hydroxide and three times with water. The ether layer was dried, and the ether removed by evaporation invacuo to yield as a residue N,N-dimethyl-3-(p-trifluoromethylphenoxy)-3phenylpropylamine.
  A solution containing 8.1 g of cyanogen bromide in 500 ml benzene and 50 ml of toluene was placed in a 1 L three-neck round-bottom flask equipped with thermometer, addition funnel, drying tube and inlet tube for nitrogen. The solution was cooled to about 5°C with stirring, and nitrogen gas was bubbled thru the solution. Next, a solution of 12.146 g of N,N-dimethyl-3-(ptrifluoromethylphenoxy)-3-phenylpropylamine dissolved in 40 ml of benzene was added in dropwise fashion. The temperature of the reaction mixture was allowed to rise slowly to room temperature, at which temperature stirring was continued overnight while still maintaining a nitrogen atmosphere 100 ml of benzene were added. The reaction mixture was washed twice with water, once with 2 N aqueous sulfuric acid and then with water until neutral. The organic layer was dried, and the solvents removed therefrom by evaporation in vacuo to yield about 9.5 g of an oil comprising N-methyl-N-cyano-3-(ptrifluoromethylphenoxy)-3

• Therapeutic Function

  Antidepressant, Anorexic

• Biologische Funktion

  Fluoxetine (Prozac) is given in the morning because of its potential for being activating and causing insomnia. Food does not affect its systemic bioavailability and may actually lessen the nausea reported by some patients. Fluoxetine is highly bound to serum proteins and may interact with other highly protein bound drugs. It is demethylated in the liver to form an active metabolite, norfluoxetine. Inactive metabolites are excreted by the kidney.Doses must be reduced in patients with liver disease.
  The slow elimination of fluoxetine and norfluoxetine lead to special clinical concerns when adjusting doses and discontinuing this medication. Steady state is not reached until 4 to 6 weeks, and similarly, complete elimination takes 4 to 6 weeks after discontinuation of the medication. A 4- to 6-week waiting period should be permitted before starting a medication with potential for an interaction with fluoxetine, such as a monoamine oxidase inhibitor (MAOI). Additionally, fluoxetine is a potent inhibitor of cytochrome P450 2D6 and can significantly elevate levels of drugs metabolized by this route. Thus, coadministration of drugs with a narrow therapeutic index, such as TCAs and type 1C antiarrhythmics, including flecainide and propafenone, are a particular concern.

• Allgemeine Beschreibung

  In fluoxetine (Prozac), protonated in vivo, the protonatedamino group can H-bond to the ether oxygen electrons, whichcan generate the β-arylamino–like group, with the other arylserving as the characteristic “extra” aryl. The S-isomer ismuch more selective for SERT than for NET. The majormetabolite is the N-demethyl compound, which is as potent asthe parent and more selective (SERT versus NET).
  Therapy for 2 or more weeks is required for the antidepressanteffect. Somatodendritic 5-HT_1A autoreceptor desensitizationwith chronic exposure to high levels of 5-HT isthe accepted explanation for the delayed effect for this andother serotonin reuptake inhibitors.

• Mechanism of action

  Fluoxetine is a potent and selective inhibitor of 5-HT reuptake, but not of NE or dopamine uptake in the CNS. Its mechanism of action is common to the SSRIs. Fluoxetine does not interact directly with postsynaptic 5-HT receptors and has weak affinity for the other neuroreceptors. Both enantiomers of fluoxetine display similar affinities for human SERT. The NE:5-HT selectivity ratio, however, indicates that the S-enantiomer is approximately 100 times more selective for SERT inhibition than the R-enantiomer. The R-(+)-stereoisomer is approximately eight times more potent an inhibitor of SERT together with a longer duration of action than the S-(–)-isomer. However, the S-(–)-norfluoxetine metabolite is seven times more potent as an inhibitor of the 5-HT transporter than the R-(+)-metabolite, with a selectivity ratio approximately equivalent to that of S-fluoxetine.

• Pharmakokinetik

  The pharmacokinetics of fluoxetine fit the general characteristics of the SSRIs. Of particular importance is its long half-life contributing to its nonlinear pharmacokinetics. In vitro studies show that fluoxetine and norfluoxetine are potent inhibitors of CYP2D6 and CYP3A4 and less potent inhibitors of CYP2C9, CYP2C19 and CYP1A2. Fluoxetine is metabolized primarily by CYP2D6 N-demethylation to its active metabolite norfluoxetine and, to a lesser extent, O-dealkylation to form the inactive metabolite p-trifluoromethylphenol. Following oral administration, fluoxetine and its metabolites are excreted principally in urine, with approximately 73% as unidentified metabolites, 10% as norfluoxetine, 10% as norfluoxetine glucuronide, 5% as fluoxetine N-glucuronide, and 2% as unmetabolized drug.
  Both R- and S-Norfluoxetine were less potent than the corresponding enantiomers of fluoxetine as inhibitors of NE uptake. Inhibition of 5-HT uptake in cerebral cortex persisted for more than 24 hours after administration of S-norfluoxetine similarly to fluoxetine. Thus, S-norfluoxetine is the active N-demethylated metabolite responsible for the persistently potent and selective inhibition of 5-HT uptake in vivo.
  The pharmacokinetics of fluoxetine in healthy geriatric individuals do not differ substantially from those in younger adults. Because of its relatively long half-life and nonlinear pharmacokinetics, the possibility of altered pharmacokinetics in geriatric individuals could exist, particularly those with systemic disease and/or in those receiving multiple medications concurrently. The elimination half-lives of fluoxetine and norfluoxetine do not appear to be altered substantially in patients with renal or hepatic impairment.

• Pharmakologie

  Fluoxetine is a phenylpropylamine that inhibits the neuronal reuptake of serotonin, which presumably has a direct relationship on antidepressant activity. This compound has either no effect or a small effect on the neuronal reuptake of norepinephrine and dopamine. In addition, it does not bind to cholinergic, histaminergic, or α-adrenergic receptors, which is believed to be the cause of tricyclic antidepressant side effects.

• Clinical Use

  Fluoxetine is a 3-phenoxy-3-phenylpropylamine that exhibits selectivity and high affinity for human SERT and low affinity for NET. It is marketed as a racemic mixture of R- and S-fluoxetine. Its selectivity for SERT inhibition depends on the position of the substituent in the phenoxy ring.

• Synthese

  Fluoxetine, 3-[p-(trifluoromethyl)-phenoxy]-N-methyl-3-phenylpropylamine (7.3.6), is synthesized by reaction of p-trifluoromethylphenol with 3-(chloro)-N-methyl-3- phenylpropylamine in the presence of potassium carbonate [59,60].

  

  
  

• Arzneimittelwechselwirkung

  Fluoxetine and its norfluoxetine metabolite, like many other drugs metabolized by CYP2D6, inhibit the activity of CYP2D6 and, potentially, may increase plasma concentrations of concurrently administered drugs that also are metabolized by this enzyme. Fluoxetine may make normal CYP2D6 metabolizers resemble poor metabolizers. Fluoxetine can inhibit its own CYP2D6 metabolism, resulting in higher-than-expected plasma concentrations during upward dose adjustments. Therefore, switching from fluoxetine to another SSRI or other serotonergic antidepressant requires a washout period of at least 5 weeks or a lowerthan-recommended initial dose with monitoring for adverse events.
  Fluoxetine is highly protein bound and may affect the free plasma concentration and, thus, the pharmacological effect of other highly protein-bound drugs (e.g., warfarin sodium).

• Stoffwechsel

  Fluoxetine is extensively metabolised by the enzyme CYP2D6 in the liver to its primary active metabolite norfluoxetine (desmethylfluoxetine), by desmethylation. The elimination half-life of fluoxetine is 4-6 days and for norfluoxetine 4-6 days. Excretion is mainly (about 60%) via the kidney.

Fluoxetine Upstream-Materialien And Downstream Produkte

Fluoxetine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(202)Suppliers

54910-89-3, Fluoxetine Verwandte Suche: